Par Pharmaceutical Companies Dividend Yield: 0.00%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PRX Dividend Yield Rankings
| Overall | 57th percentile | 1971 of 4678 |
| Sector | 86th percentile | 73 of 531 in Healthcare |
| Industry | 84th percentile | 2 of 13 in Drugs - Generic |
PRX Dividend Yield Range, Past 5 Years
| Minimum | 0.00% | Mar 1999 |
| Maximum | 0.00% | Mar 1999 |
| Average |
About Dividend Yield
The dividend yield is the sum company's annual dividends per share, divided by the current price per share. It is often expressed as a percentage. It the reciprocal of the price/dividend ratio. By investing in a company with a high dividend yield, investors can secure a relatively stable cash flow. However, it is important to note that sometimes dividend yields are high when a company is facing financial trouble, and the company may cut the dividend in the near future.
For example, if a stock trades at $36 and pays $1.80 in dividends over the course of one year ($.45 per quarter), the company's dividend yield is 5%.
Learn More
You may also be interested in these PRX related companies
PRX News
Robbins Umeda LLP Announces an Investigation of Par Pharmaceutical Companies, Inc.
Feb 06, 12:01PM Business Wire
Feb 06, 12:01PM Business Wire
$PRX New 52 Week High - Crossed daily highs resistance. Next resistance 39.00 from 1/4/2011.
about 9 days ago by TradeIdeasQuant
about 9 days ago by TradeIdeasQuant
Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2011 Results on February 28, 2012
Jan 31, 9:00AM PR Newswire
Jan 31, 9:00AM PR Newswire
I don't think the pricing fixing case against $PRX is going to have much of an effect. Last I checked they have about 50 other products..
about 29 days ago by bradloncar
about 29 days ago by bradloncar
UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Shaping Up To Be Strong Growth Story
Jan 09, 10:51AM Street Insider
Jan 09, 10:51AM Street Insider
Needham & Company: Thoughts Heading Into Par Pharmaceutical's (PRX) January 6, Analyst Day; Generics Take Center Stage
Jan 06, 11:20AM Street Insider
Jan 06, 11:20AM Street Insider
Listen to $PRX Par Pharmaceutical Companies Investor Day - live at 09:00 AM, ondemand after - http://stks.co/1nwc
about 37 days ago by earningscast
about 37 days ago by earningscast
Leerink Swann Remains Positive on Shares of Par Pharmaceutical (PRX) Following Meeting With Management
Nov 30, 10:59AM Street Insider
Nov 30, 10:59AM Street Insider
Par Pharma promotes Thomas Haughey to President and Paul Campanell as COO
Nov 22, 8:36AM FlyOnTheWall
Nov 22, 8:36AM FlyOnTheWall
Magic Formula Links for 8/24/2011 $AMAT $GTAT $MHP $PRX $GME http://stks.co/1Bx
about 172 days ago by MagicDiligence
about 172 days ago by MagicDiligence
Intellipharmaceutics and Par Expand Development and Commercialization Agreement $IPCI $PRX http://stks.co/PK
about 178 days ago by IPCI
about 178 days ago by IPCI
$PRX http://chart.ly/jeylvad it was the gap up and close back over the 20-day MA so maybe over $25 or $25.40 on good volume
about 262 days ago by StockTiger
about 262 days ago by StockTiger
Par Pharma - Buried in the Generic Drugs Battlefield $PRX $TEVA $WPI $MYL $NVS http://stk.ly/kB9i9C
about 276 days ago by MagicDiligence
about 276 days ago by MagicDiligence
$PRX $34.97 HAUGHEY THOMAS officer (EVP, CAO, General Counsel) S 198,860 @ $34.76 amnt $6,913,347 proc'd ($40,803) 5/10/2011
about 277 days ago by canarionyc
about 277 days ago by canarionyc
$PRX http://chart.ly/wp6ct45 from watch list - not a big move from today's trigger but volume good at 167% of ave full day
about 279 days ago by StockTiger
about 279 days ago by StockTiger
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PRX | 36.55 | -0.50 | -1.35% | 1.33B |
| ABAX | 27.49 | -0.41 | -1.47% | 595.98M |
| MOV | 18.85 | 0.00 | 0.00% | 343.64M |
| YHOO | 16.14 | 0.14 | 0.88% | 20.02B |
| AAP | 79.99 | -0.13 | -0.16% | 6.13B |
| GMCR | 62.85 | -1.40 | -2.18% | 9.72B |
| HUN | 13.38 | -0.02 | -0.15% | 3.24B |
| ATI | 45.58 | -2.10 | -4.40% | 4.85B |
| CTCT | 30.63 | 0.22 | 0.72% | 910.94M |
| LNT | 43.08 | -0.28 | -0.65% | 4.78B |
